Spots Global Cancer Trial Database for gleevec
Every month we try and update this database with for gleevec cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting | NCT00877045 | Gastrointestina... | 18 Years - | SCRI Development Innovations, LLC | ||
| Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) | NCT00290485 | Gastrointestina... | Imatinib mesyla... | 18 Years - | Maisonneuve-Rosemont Hospital | |
| Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST | NCT00500188 | Gastrointestina... | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | NCT00386373 | Leukemia | Imatinib Mesyla... | 16 Years - | M.D. Anderson Cancer Center | |
| Therapy of Early Chronic Phase CML With Gleevec | NCT00048672 | Leukemia, Myelo... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer | NCT00485485 | Head and Neck C... Squamous Cell C... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | NCT00861471 | Prostate Cancer Prostatic Neopl... | Docetaxel Imatinib Mesyla... | 18 Years - | NYU Langone Health | |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | NCT00499889 | Leukemia | Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans... | - 70 Years | M.D. Anderson Cancer Center | |
| New Individualized Therapy Trial for Metastatic Colorectal Cancer | NCT00867334 | Colorectal Neop... Colorectal Canc... | Imatinib mesyla... Standard-of-car... | 18 Years - | Inova Health Care Services | |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | NCT00038675 | Chronic Myelomo... Chronic Myeloid... Polycythemia Ve... Hypereosinophil... Mastocytosis | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors | NCT00580281 | Gastric Cancer Leukemia Chronic Myeloge... | blood test, uri... | - | Memorial Sloan Kettering Cancer Center | |
| Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | NCT01031628 | Gastrointestina... | Imatinib mesyla... Imatinib mesyla... Imatinib mesyla... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | NCT01011075 | Non-small Cell ... | Imatinib mesyla... Paclitaxel | 70 Years - | New Mexico Cancer Care Alliance | |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) | NCT00050531 | Leukemia, Myelo... | Gleevec Peg-alpha inter... Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | NCT03589326 | Philadelphia Ch... | Ponatinib Imatinib Vincristine Dexamethasone Cytarabine Methotrexate Prednisone | 18 Years - | Takeda | |
| Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | NCT01011075 | Non-small Cell ... | Imatinib mesyla... Paclitaxel | 70 Years - | New Mexico Cancer Care Alliance | |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | NCT00038649 | Myelogenous Leu... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | NCT00415909 | Chronic Myeloge... | Imatinib Mesyla... TALL-104 cells | 18 Years - | M.D. Anderson Cancer Center | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | NCT00038675 | Chronic Myelomo... Chronic Myeloid... Polycythemia Ve... Hypereosinophil... Mastocytosis | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Gleevec Study for Patients With Ovarian Cancer | NCT00510653 | Ovarian Cancer | Imatinib Mesyla... | 18 Years - | M.D. Anderson Cancer Center | |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | NCT00038649 | Myelogenous Leu... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas | NCT01140360 | Neurofibromatos... Neurofibromas | Gleevec | 3 Years - 65 Years | Indiana University | |
| Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | NCT00506779 | Uterine Cancer | Imatinib Mesyla... Paclitaxel | - | M.D. Anderson Cancer Center | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | NCT01031628 | Gastrointestina... | Imatinib mesyla... Imatinib mesyla... Imatinib mesyla... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC | NCT00156286 | Small Cell Lung... | Gleevec | 18 Years - | University of Michigan Rogel Cancer Center | |
| Late Chronic Phase Chronic Myelogenous Leukemia | NCT01092741 | Leukemia | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors | NCT00580281 | Gastric Cancer Leukemia Chronic Myeloge... | blood test, uri... | - | Memorial Sloan Kettering Cancer Center | |
| Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | NCT00615927 | Glioblastoma Gliosarcoma | Imatinib Mesyla... | 18 Years - | Duke University | |
| Imatinib Mesylate in Treating Patients With Metastatic Melanoma | NCT00027586 | Melanoma Skin Neoplasms | Imatinib mesyla... | - | M.D. Anderson Cancer Center | |
| Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia | NCT00079313 | Chronic Myelomo... Chronic Myeloge... | Imatinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Late Chronic Phase Chronic Myelogenous Leukemia | NCT01092741 | Leukemia | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Ph II Study of Perifosine Plus Gleevec for Patients With GIST | NCT00455559 | Gastrointestina... | Perifosine Imatinib Mesyla... | 18 Years - | AEterna Zentaris | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes | NCT00451997 | Leukemia, Myelo... Myelodysplastic... | Gleevec Ara-C | 60 Years - | M.D. Anderson Cancer Center | |
| Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | NCT01083589 | Non-small Cell ... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Imatinib Mesylate in Treating Patients With Metastatic Melanoma | NCT00027586 | Melanoma Skin Neoplasms | Imatinib mesyla... | - | M.D. Anderson Cancer Center | |
| A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | NCT01294202 | Gastrointestina... | AT13387 and Ima... | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01673009 | Neurofibromatos... | Gleevec | 3 Years - 65 Years | Indiana University | |
| A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) | NCT01011998 | Chronic Myeloge... | Gleevec (imatin... | 18 Years - | New Mexico Cancer Care Alliance | |
| Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | NCT00684411 | T Cell Non-Hodg... | Imatinib mesyla... | 18 Years - | Dana-Farber Cancer Institute | |
| Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients | NCT00558961 | Chronic Lymphoc... | Gleevec and Chl... | 18 Years - | Jewish General Hospital | |
| A Study of Imatinib and Docetaxel in Prostate Cancer | NCT00251225 | Prostate Cancer | Gleevec Docetaxel | 18 Years - | University of Pittsburgh | |
| Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC | NCT00156286 | Small Cell Lung... | Gleevec | 18 Years - | University of Michigan Rogel Cancer Center | |
| Therapy of Early Chronic Phase CML With Gleevec | NCT00048672 | Leukemia, Myelo... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| New Individualized Therapy Trial for Metastatic Colorectal Cancer | NCT00867334 | Colorectal Neop... Colorectal Canc... | Imatinib mesyla... Standard-of-car... | 18 Years - | Inova Health Care Services | |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | NCT00861471 | Prostate Cancer Prostatic Neopl... | Docetaxel Imatinib Mesyla... | 18 Years - | NYU Langone Health | |
| Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients | NCT00558961 | Chronic Lymphoc... | Gleevec and Chl... | 18 Years - | Jewish General Hospital | |
| Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | NCT01011075 | Non-small Cell ... | Imatinib mesyla... Paclitaxel | 70 Years - | New Mexico Cancer Care Alliance | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| Glivec Phase II Pediatric Study | NCT00180830 | Cancer | Glivec Gleevec | 6 Months - 21 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | NCT00500110 | Prostate Cancer | Docetaxel Imatinib Mesyla... Leuprolide Goserelin Aceta... | - | M.D. Anderson Cancer Center | |
| Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma | NCT00402766 | Mesothelioma | Cisplatin Imatinib Mesyla... Pemetrexed Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | NCT00354913 | Glioblastoma Gliosarcoma | hydroxyurea imatinib mesyla... | 18 Years - | Duke University | |
| Study of Temzolomide and Gleevec in Advanced Melanoma | NCT00667953 | Melanoma Advanced Melano... | Gleevec Temodar | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT00081926 | Chronic Myeloge... | Gleevec | 18 Years - | Novartis | |
| Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) | NCT00415857 | Leukemia | Peptide Vaccine... Peginterferon a... Imatinib GM-CSF | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Imatinib and Docetaxel in Prostate Cancer | NCT00251225 | Prostate Cancer | Gleevec Docetaxel | 18 Years - | University of Pittsburgh | |
| Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | NCT01083589 | Non-small Cell ... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | NCT00136409 | Myelofibrosis Myeloid Metapla... Agnogenic Myelo... Chronic Myelomo... | Imatinib mesyla... | 18 Years - | Dana-Farber Cancer Institute | |
| Therapy of Early Chronic Phase CML With Gleevec | NCT00048672 | Leukemia, Myelo... | Gleevec | 15 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
